Authors:
Ibrahim, NK
Valero, V
Rahman, Z
Theriault, RL
Walters, RS
Buzdar, AU
Booser, DJ
Holmes, FA
Murray, DJ
Willey, J
Bast, R
Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466
Authors:
Hortobagyi, GN
Buzdar, AU
Theriault, RL
Valero, V
Frye, D
Booser, DJ
Holmes, FA
Giralt, S
Khouri, I
Andersson, B
Gajewski, JL
Rondon, G
Smith, TL
Singletary, SE
Ames, FC
Sneige, N
Strom, EA
McNeese, MD
Deisseroth, AB
Champlin, RE
Citation: Gn. Hortobagyi et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J NAT CANC, 92(3), 2000, pp. 225-233
Authors:
Esteva, FJ
Soh, LT
Holmes, FA
Plunkett, W
Meyers, CA
Forman, AD
Hortobagyi, GN
Citation: Fj. Esteva et al., Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer, CANC CHEMOT, 46(5), 2000, pp. 382-386
Authors:
Booser, DJ
Walters, RS
Holmes, FA
Hortobagyi, GN
Citation: Dj. Booser et al., Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatinfor relapsed metastatic breast cancer: A phase II study, AM J CL ONC, 23(1), 2000, pp. 40-41
Authors:
Rivera, E
Holmes, FA
Frye, D
Valero, V
Theriault, RL
Booser, D
Walters, R
Buzdar, AU
Dhingra, K
Fraschini, G
Hortobagyi, GN
Citation: E. Rivera et al., Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy, CANCER, 89(11), 2000, pp. 2195-2201
Authors:
Holmes, FA
Valero, V
Walters, RS
Theriault, RL
Booser, DJ
Gibbs, H
Fraschini, G
Buzdar, AU
Willey, J
Frye, D
Asmar, L
Hortobagyi, GN
Citation: Fa. Holmes et al., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results, ANN ONCOL, 10(4), 1999, pp. 403-411
Authors:
Pusztai, L
Holmes, FA
Fraschini, G
Hortobagyi, GN
Citation: L. Pusztai et al., Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy, CANC CHEMOT, 43(1), 1999, pp. 86-91
Authors:
Cristofanilli, M
Holmes, FA
Esparza, L
Valero, V
Buzdar, AU
Neidhart, JA
Hortobagyi, GN
Citation: M. Cristofanilli et al., Phase I II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience, BREAST CANC, 54(3), 1999, pp. 225-233